Log in
Enquire now
‌

US Patent 7572453 Chimeric alphavirus replicon particles

Patent 7572453 was granted and assigned to Novartis on August, 2009 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Novartis
Novartis
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
75724530
Patent Inventor Names
Kent Thudium0
Silvia Perri0
John M. Polo0
Date of Patent
August 11, 2009
0
Patent Application Number
113976690
Date Filed
April 3, 2006
0
Patent Citations Received
‌
US Patent 12134777 Alphavirus replicon vector and immunotherapy by administering same
0
‌
US Patent 11771747 Multiepitope vaccine cassettes
‌
US Patent 12060568 Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
0
‌
US Patent 12109257 Alphavirus neoantigen vectors
0
Patent Primary Examiner
‌
Mary E. Mosher
0
Patent abstract

Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7572453 Chimeric alphavirus replicon particles

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.